GammaTile by GT Medical Technologies, Inc.

The GammaTile team is pleased to announce the interim results of the Phase 3 Randomized Controlled Trial, which were recently presented at the 2025 Congress of Neurological Surgeons Annual Meeting. The study found that GammaTile reduced the risk of tumor recurrence or death by more than 50% compared to standard of care (surgery followed by delayed stereotactic radiation). Importantly, these gains were achieved without any increase in treatment-related side effects, reinforcing the safety and efficacy of immediate, targeted radiation delivered at surgery.(1) The findings represent a significant step forward in brain metastasis care and highlight the growing impact of GammaTile in improving patient outcomes. Together, we’re changing what’s possible for patients with brain tumors, delivering immediate radiation when and where it is needed most. Read the press release to learn more: tinyurl.com/8mpnavwj This interim analysis is based on data from 168 of the 230 patients enrolled in the study. Randomization was conducted on a 1:1 basis. All results presented are preliminary and subject to change as additional data become available from the remaining enrolled participants. REFERENCE: Weinberg J, Beckham TH, Lin H, et al. Interim analysis of a phase 3 randomized controlled trial for treatment of newly diagnosed metastatic brain tumors(ROADS, NCT04365374).

NEW CLINICAL DATA: The GammaTile team sat down with neurosurgeon Matthew J. Shepard, MD, for the latest episode of our NeuroNexus Webinar Series, “Local Control and LMD After Resection and GammaTile Brachytherapy for Newly Diagnosed Brain Metastases: Results from the STaRT Registry.” Dr. Shepard discussed key findings from the Prospective Registry study published in the Journal of Neuro-Oncology, which reported high local control and low overall toxicity at 12 months in patients with newly diagnosed brain metastases.(1) Watch now: na2.hubs.ly/H04mRWJ0 Quotes are based on the personal experience and learnings of the featured healthcare professionals. See full prescribing information at na2.hubs.ly/H04mR4s0 REFERENCE: 1. Kite T, Hanft S, Zeller S, et al. Local control and leptomeningeal disease after resection and GammaTile brachytherapy for newly diagnosed brain metastases: results from a prospective study. J Neurooncol. 2026;176(3):199.

Hear from M Health Fairview University of Minnesota Medical Center’s (@UMNRadOnc) Lindsey Sloan, MD, PhD, on her experience as a GammaTile Center of Excellence (COE) program physician. Dr. Sloan is an assistant professor in the Department of Radiation Oncology and a Radiobiologist at the Masonic Cancer Center in the University of Minnesota Brain Tumor Program. To find a GammaTile COE near you, select the “Center of Excellence” filter: na2.hubs.ly/H04kmM00 Quotes are based on the personal experience and learnings of the featured healthcare professionals. See full prescribing information at na2.hubs.ly/H04kmpH0

GT Medical Technologies’ Mike Garcia, MD, MS, was recently featured in BrachyBites, a podcast by the American Brachytherapy Society (@AmericanBrachy). In this episode, host Manuj Agarwal, MD, interviews Dr. Garcia who breaks down the clinical problem that GammaTile was designed to solve: the vulnerability of the postoperative treatment gap in brain tumor care. Dr. Garcia discusses patient selection, preoperative planning, workflow, barriers to adoption, and the ROADS interim data. This conversation explores the evidence, the biology, and what comes next for tile-based radiation therapy. Listen now on Spotify: na2.hubs.ly/H04dDzm0 Listen now on Apple Podcasts: na2.hubs.ly/H04dDBd0 See full prescribing information at na2.hubs.ly/H04dC7W0

We are thrilled to announce M Health Fairview University of Minnesota Medical Center as the latest designation to our GammaTile Center of Excellence (COE) Program! This recognition acknowledges institutions and their physicians who have achieved an exceptional level of clinical expertise and experience in the GammaTile procedure and display an overall dedication to patient education and improving outcomes. The following physicians have received this recognition: • Lindsey Sloan, MD, PhD, Radiation Oncologist • Andrew Venteicher, MD, PhD, Neurosurgeon • Daniel Guillaume, MD, MS, Neurosurgeon • Robert McGovern III, MD, Neurosurgeon • Matthew Hunt, MD, Neurosurgeon • Elizabeth Neil, MD, Neuro-Oncologist Read the press release: na2.hubs.ly/H04dxyx0 See full prescribing information at na2.hubs.ly/H04dyY10

We are proud to introduce the new GammaTile Patient Resource Center, a centralized hub designed to support patient education and informed conversations around GammaTile. Explore a collection of resources including downloadable patient education materials and patient testimonials to help guide discussions with patients and caregivers. Access here: na2.hubs.ly/H04bQ9q0

This past weekend, we proudly hosted the 5th Annual GammaTile Practitioners Society (GPS) Meeting in Scottsdale, AZ. It was the largest GPS to date, with close to 100 radiation oncologists, neurosurgeons, physicists and administrators coming together to engage in clinical discussions with their peers. This year’s GPS featured dynamic clinical presentations and peer-led discussions focused on the latest emerging data supporting tile-based radiation therapy (TBRT), best practices for GammaTile use, and the latest thinking on operable brain tumor treatments. The collaboration, insights, and shared commitment to improving outcomes made for an impactful and inspiring weekend. Thank you to everyone who attended GPS for your contributions to a very successful event!

On Employee Appreciation Day, we want to recognize the dedication, innovation, and passion our team brings to our mission every day. Every milestone is made possible by the talent and commitment of our GammaTile team. We look forward to the year ahead as we continue working together to improve the lives of patients with brain tumors.

Our Centers of Excellence (COE) program recognizes institutions and their physicians who have achieved an exceptional level of clinical expertise and experience in the GammaTile procedure and display an overall dedication to patient education and improving outcomes. Learn more about the program in our HCP Resource Center: na2.hubs.ly/H04401f0 See full prescribing information at na2.hubs.ly/H0441WS0

We look forward to hearing @TedSchwartz13 and other expert perspectives at the 2026 GammaTile Practitioners Society event this weekend!

We are pleased to announce the publication of prospective, multicenter Phase IV registry data evaluating clinical outcomes following surgical resection with immediate, localized GammaTile radiation therapy in patients with newly diagnosed brain metastases. The study, published in the Journal of Neuro-Oncology, reports local control, leptomeningeal disease and safety outcomes at 12 months. This study reports peer-reviewed safety and efficacy data from the prospective, multicenter GammaTile Phase IV Registry, which has enrolled more than 600 patients to date. Read the press release: na2.hubs.ly/H03Y2Ds0 See full prescribing information at na2.hubs.ly/H03Y2tb0

Join the GammaTile team next week at the North American Skull Base Society Annual Meeting in San Diego, California. The NASBS Annual Meeting is a premier gathering for specialists in skull base surgery, bringing together experts from neurosurgery, otolaryngology, head and neck surgery, plastic surgery, and related fields. Learn more about the meeting: na2.hubs.ly/H03WHFD0

Hear firsthand from healthcare providers on their clinical experience with GammaTile. The Clinical Perspectives playlist on our YouTube channel contains insights from neurosurgeons, radiation oncologists, neuro-oncologists and medical physicists nationwide. Watch now: na2.hubs.ly/H03TYhg0 See full prescribing information at na2.hubs.ly/H03TYbx0

Hear directly from physicians about their clinical experience with GammaTile as a treatment for patients with operable brain tumors on our YouTube channel! From panel discussions to webinar episodes, our Clinical Education playlist features in-depth conversations from physicians using GammaTile in practice today. Explore the playlist: na2.hubs.ly/H03R68m0 See full prescribing information at na2.hubs.ly/H03R83L0

Join the GammaTile team next week at the 2026 Mayfield Winter Clinics (@MayfieldClinic). GammaTile will be exhibiting during the cranial section Tuesday (2/24) through Thursday (2/26). The Winter Clinics for Cranial and Spinal Surgery bring together nationally recognized neurosurgeons and orthopaedic surgeons for educational programming on today’s most pressing topics. Register today: na2.hubs.ly/H03PB_z0

It’s been one year since we launched our LinkedIn GammaTile Showcase Page to create a dedicated space for product updates, clinical insights, and event news. If you haven’t connected with us there yet, we invite you to join our growing community and stay up-to-date with GammaTile. Follow here: na2.hubs.ly/H03MY3k0

Join leading experts for a case-based discussion on Non-Traditional Brachytherapy, presented by ACRO, ROVER, ABS, and GammaTile. This educational session will explore innovative approaches to brachytherapy through real-world cases and faculty-led insights. Register today: na2.hubs.ly/H03DJx30

Join leading experts for a case-based discussion on Non-Traditional Brachytherapy, presented by ACRO, ROVER, ABS, and GammaTile. This educational session will explore innovative approaches to brachytherapy through real-world cases and faculty-led insights. Register today: na2.hubs.ly/H03zXFZ0

Today and every day, we stand alongside those whose lives have been touched by cancer. We recognize all of the patients and caregivers who navigate these difficult journeys, as well as the physicians who work tirelessly in their fight to improve outcomes and provide quality care to their patients. At GammaTile, we remain committed to our mission of improving the lives of patients with operable brain tumors. #WorldCancerDay #GammaTile